The Unusual Call Buying That Just Woke Up a Mega-Cap Biotech

Traders piled into calls at twice the normal volume last week. The catalyst isn't earnings; it's a twice-yearly injectable that could reshape a multi-billion-dollar prevention market. And the setup looks tight.

Uranium Demand Tightens (Sponsored)

Nuclear Stocks Are Back - Here Are 7 to Watch

Multiple nuclear stocks surged over the past year as cash flow jumped, contracts expanded, and uranium demand tightened.

Our analysts believe the next phase of the move is still ahead.

7 Top Nuclear Stocks to Buy Now reveals the companies positioned across the sector - from high-growth uranium and next-generation reactor plays to steadier, contract-backed nuclear services names.

You can get the full list free today - access your copy before it disappears behind the paywall.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our Privacy Policy. Unsubscribe at any time.)

Gilead Sciences

August 18 – Pre‑market
Ticker: GILD | Sector: Healthcare (Drug Manufacturers) | Market Cap: $177.86B

30‑Second Take

On August 13, roughly 16,649 GILD calls were bought, more than double the normal daily volume, per unusual options activity feeds. That kind of positioning doesn't happen for a sleepy quarter. It happens when someone thinks a re-rating is coming.

And the setup here is bigger than one earnings print. Gilead's twice-yearly HIV prevention shot (Yeztugo/lenacapavir) is still early in its commercial ramp, and the market is modeling it like a slow biotech launch.

It isn't. You've got a large-cap name with a 2%+ yield and a defensive beta, sitting mid-range, with a big buyer loading calls. That's the setup.

Trade Setup

Timeframe: 4 to 12 weeks
Edge type: Options positioning plus underappreciated commercial launch

Unusual call flow printed last week at more than twice average daily call volume. That's your signal a bigger buyer sees near-term upside. Pair it with a still-early launch of a first-in-class twice-yearly HIV prevention drug, and the reason to be long isn't a mystery.

You want to be in before the Street models the ramp correctly. Entry on strength, size modestly, add on any pullback that holds the $130 shelf.

Dividend Yield Leaders (Sponsored)

7 High Yield Dividend Stocks to Buy Now

Love steady payouts?

This free report reveals 7 high-yield dividend stocks you need to know about.

From Company #3, a tobacco giant innovating with smokeless products, to Company #4, famously known as “The Monthly Dividend Company,” these picks deliver steady income you can count on.

Perfect for income-focused investors.

Download the Free Dividend Report Now

(By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time. - Privacy Policy)

As we move toward the end of summer, what's your primary focus for the rest of the investing year?

Finding 1–2 new high-conviction ideas to add before year-end

Reviewing my existing portfolio and trimming what no longer makes sense

Building cash — I expect better opportunities in the fall

Staying the course — my process doesn't change with the calendar

Snapshot Table

Metric	Value	Current Stance
Price	$143.44	Upper half of 52-week range
52-Week Range	$108.46 - $157.29	Room to the high
Market Cap	$177.86B	Large-cap defensive
P/E Ratio	18.7 (TTM)	Reasonable for large-cap pharma
Dividend Yield	2.3%	Income while you wait
Beta	0.34	Low volatility vs market

Chart

1-month trading summary: GILD has been grinding higher inside the upper half of its 52-week range. Price action has been the opposite of dramatic, which is exactly what you want before a catalyst.

Low beta, tight range, a name institutions accumulate without headlines. Then last Wednesday, the call flow blew out. That's the tell that some larger money thinks the range is about to break to the upside.

Bull Case

The core story here is misread. The Street still values Gilead as a mature HIV franchise plus a mediocre oncology bolt-on. What you're actually looking at is more interesting.

Yeztugo, the twice-yearly injectable for HIV prevention, is a genuinely category-defining product. Prior PrEP drugs required a daily pill. Yeztugo is two shots a year. Adherence, insurance coverage, and payer economics all move in Gilead's favor once uptake accelerates, and you're looking at an addressable market that runs into the tens of billions globally.

Now look at the options flow. Roughly 16,649 GILD calls printed on August 13, more than double normal volume. That kind of flow is unusual for a mega-cap defensive name. Somebody is paying up for upside exposure, and they aren't doing it at random. If you're sizing a GILD position, that August 13 print is your tell.

Add in the shape of the business: a low beta, a trailing yield of around 2.36%, and a valuation that trades at a real discount to the broader biotech group. You get downside cushion while you wait.

If you already own defensive healthcare, this is where you add. If you don't, this is a name where you can be early without paying growth-stock multiples for the option value.

Bear Case

You need to be honest about what could break this.

First, patent expirations. Gilead's older HIV franchise (Biktarvy in particular) faces a loss of exclusivity in the mid-2030s. Generic competition isn't expected to arrive until April 2036 under current settlement agreements, but the market has been trying to price that overhang for years. If Yeztugo doesn't ramp fast enough, your pipeline math gets uncomfortable.

Second, launch execution. New drugs live and die on payer coverage, physician education, and patient adherence infrastructure. A twice-yearly injectable requires a different distribution model than a pill. Any hiccup on insurance access or specialty pharmacy logistics, and your underappreciated launch thesis turns into another slow drug launch.

Third, options flow can be a head fake. Just because someone bought 16,000 calls doesn't mean they're right. It could be a hedge against a larger short. Don't confuse activity for conviction until price confirms.

Fourth, healthcare policy risk is real. Pricing pressure on branded drugs continues to be a Washington story that flares up unpredictably. A defensive name with government exposure isn't insulated from that.

If the launch data over the next two quarters shows a slower ramp than expected, this stock can drift back to the $120s in a hurry. Size accordingly.

Quick Checklist

✅ Thesis still valid after today's close
✅ Volume confirms move above key levels
✅ Catalyst date double-checked (today's date)

Deep‑Dive Links

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha

Everyday Alpha is a publication of Elite Trade Media LLC.

Disclosure: Content is for informational and entertainment purposes only and is not investment advice. Do not base investment decisions on this newsletter. Securities mentioned may be owned by our owners or operators, which could affect our objectivity. Consult a licensed financial advisor before making any investment decision. We may receive compensation from advertisers and affiliate links in this email, including for featured third-party offers.

Everyday Alpha and its parent company are not registered investment advisors, broker-dealers, or financial planners. Nothing published by Everyday Alpha — including but not limited to newsletters, emails, text messages, social media posts, or website content — constitutes personalized investment advice, a recommendation to buy or sell any security, or an offer or solicitation to purchase or sell any financial instrument.

All content is provided strictly for informational and educational purposes. You should not rely on any content published by Everyday Alpha as a substitute for professional financial, legal, or tax advice tailored to your individual circumstances. Always consult a qualified, licensed financial advisor before making any investment decision.

Forward-Looking Statements: Content may contain forward-looking statements, including projections, opinions, and expectations regarding future events or financial performance. These statements are based on current information and assumptions at the time of writing and are inherently uncertain. Actual results may differ materially. Everyday Alpha is under no obligation to update or revise any forward-looking statement after publication.

No Guarantee of Accuracy: While Everyday Alpha strives for accuracy, we make no representation or warranty — express or implied — regarding the completeness, reliability, or timeliness of any information provided. Errors, omissions, and outdated information may occur. All content is provided "as is" without warranty of any kind.

Past Performance: Any reference to past performance of a security, strategy, or index is not indicative of future results. All investments carry risk, including the potential loss of principal. You could lose some or all of your invested capital.

Editorial Process Disclosure: Everyday Alpha uses proprietary research tools, including AI, in its editorial process. All content is reviewed and approved by our editorial team before publication. Readers should independently verify any information before making financial decisions.

Advertising & Affiliate Disclosure: Everyday Alpha receives compensation from third-party advertisers and may include paid promotions, sponsored content, and affiliate links within its publications. When you click on certain links or sign up for third-party services featured in our content, we may receive a commission or flat fee. This compensation may influence which companies or products are covered and how they are presented, though it does not affect our editorial opinions. Sponsored content is provided by advertisers and does not represent the views of Everyday Alpha.

Conflicts of Interest: Contributors, editors, and affiliates of Everyday Alpha may hold positions in securities discussed in our content. These positions may be established or liquidated at any time without notice to readers.

Limitation of Liability: Under no circumstances shall Everyday Alpha, its owners, employees, affiliates, or contributors be liable for any direct, indirect, incidental, consequential, or punitive damages arising from your use of or reliance on any content published by Everyday Alpha.

By reading, subscribing to, or otherwise engaging with Everyday Alpha content, you acknowledge and agree to the terms above.

Update your email preferences or unsubscribe here

1032 E Brandon Blvd #9644
Brandon, FL 33511, United States

Sponsored Links